[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-001", "question": "A 26-year-old G2P1 at 30 weeks' gestation presents with new-onset severe occipital headache, visual scotomata, and right upper quadrant pain. BP is 168/108 mmHg, HR 88, reflexes 3+ with 1-2 beats of clonus. Fetal heart tracing is category I. Labs: platelets 86,000/µL, AST 145 U/L, ALT 162 U/L, creatinine 0.9 mg/dL, urine protein/creatinine ratio 0.5. She received 10 mg IV hydralazine in triage 20 minutes ago; current BP is 162/104 mmHg. She desires future fertility and vaginal delivery if safe. What is the most appropriate NEXT step in management?", "options": ["Administer IV labetalol now and plan for induction of labor at 34 weeks", "Initiate magnesium sulfate and proceed with immediate induction of labor", "Initiate magnesium sulfate and administer betamethasone; plan delivery within 24 hours", "Administer additional IV hydralazine and observe; defer delivery until 34 weeks if blood pressure controlled", "Start oral labetalol and discharge with close outpatient follow-up and twice-weekly NSTs"], "answer": "C", "answer_index": 2, "explanation": "She has preeclampsia with severe features and evolving HELLP (thrombocytopenia, RUQ pain, transaminitis) at 30 weeks. For severe features <34 weeks, optimal care is magnesium, corticosteroids, and expedited delivery within 24 hours at a tertiary center, not expectant management. Immediate induction ignores steroid window and maternal stability; outpatient or prolonged expectant management is unsafe given platelets <100,000 and worsening symptoms.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 30 weeks' gestation, severe hypertension (168/108 mmHg persistent after hydralazine), neurological symptoms (severe occipital headache, visual scotomata), RUQ pain, thrombocytopenia (86,000/µL), transaminitis (AST 145 U/L, ALT 162 U/L), proteinuria (P/C 0.5), hyperreflexia with clonus, but normal creatinine (0.9 mg/dL) and category I fetal tracing, indicating severe preeclampsia with HELLP features requiring prompt intervention while optimizing fetal maturity. These support magnesium for seizure prophylaxis, betamethasone for lung maturity, and expedited delivery, making C the best fit.\\nMain logical issue(s), if any: None; the stem provides sufficient details for discriminating C as uniquely best, with alternatives inferior (A/D defer delivery unsafely, B omits steroids, E discharges inappropriately).\\nMain medical accuracy issue(s), if any: Mostly accurate per ACOG guidelines for severe preeclampsia <34 weeks, but 'plan delivery within 24 hours' slightly misses nuance of typical 48-hour window post-betamethasone for full fetal benefit if maternal/fetal stability allows; rationale correctly emphasizes avoiding expectant management due to low platelets and symptoms.\\nMinimal fix: Revise option C to 'Initiate magnesium sulfate and administer betamethasone; plan delivery in 48 hours if stable'.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 30 weeks' gestation, severe hypertension (168/108 mmHg persistent after hydralazine), neurological symptoms (severe occipital headache, visual scotomata), RUQ pain, thrombocytopenia (86,000/µL), transaminitis (AST 145 U/L, ALT 162 U/L), proteinuria (P/C 0.5), hyperreflexia with clonus, but normal creatinine (0.9 mg/dL) and category I fetal tracing, indicating severe preeclampsia with HELLP features requiring prompt intervention while optimizing fetal maturity. These support magnesium for seizure prophylaxis, betamethasone for lung maturity, and expedited delivery, making C the best fit.\nMain logical issue(s), if any: None; the stem provides sufficient details for discriminating C as uniquely best, with alternatives inferior (A/D defer delivery unsafely, B omits steroids, E discharges inappropriately).\nMain medical accuracy issue(s), if any: Mostly accurate per ACOG guidelines for severe preeclampsia <34 weeks, but 'plan delivery within 24 hours' slightly misses nuance of typical 48-hour window post-betamethasone for full fetal benefit if maternal/fetal stability allows; rationale correctly emphasizes avoiding expectant management due to low platelets and symptoms.\nMinimal fix: Revise option C to 'Initiate magnesium sulfate and administer betamethasone; plan delivery in 48 hours if stable'.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-002", "question": "A 58-year-old man with ischemic cardiomyopathy (LVEF 20%), CRT-D in place, and NYHA class III symptoms despite optimal GDMT (sacubitril/valsartan, carvedilol, spironolactone, empagliflozin, loop diuretic) presents with weight gain and dyspnea. BP 104/66 mmHg, HR 72 (biventricular paced), JVP 12 cm, bibasilar crackles, moderate ascites, no peripheral edema. Labs: Na 130 mEq/L, K 4.4, creatinine 1.8 (baseline 1.3), NT-proBNP 12,000 pg/mL. Echo: LVEF 20%, severe functional MR, normal RV size, mildly reduced RV function, PASP 55 mmHg. Right heart cath: RAP 18 mmHg, PCWP 32 mmHg, CI 1.7 L/min/m², SVR 2100 dyn·s/cm⁵. After IV diuresis, he remains hypotensive with CI 1.6. He is INTERMACS profile 4. What is the best definitive next step?", "options": ["Add continuous IV milrinone as palliative inotropic therapy without advanced therapies", "Refer for urgent isolated cardiac transplantation listing status 2 without LVAD bridge", "Evaluate for transcatheter edge-to-edge repair (TEER) of the mitral valve to reduce MR", "Refer for durable LVAD implantation as bridge to transplant or destination therapy", "Implant a percutaneous Impella device as bridge to decision in the ICU"], "answer": "D", "answer_index": 3, "explanation": "He has advanced, stage D HFrEF with persistent low-output symptoms, high filling pressures, and INTERMACS profile 4, making him appropriate for durable LVAD as bridge to transplant or destination. Isolated transplant without LVAD is not ideal given instability; TEER is for less advanced, stable patients. Chronic inotropes or short-term MCS alone are not definitive strategies in a transplant/LVAD candidate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include INTERMACS profile 4 (recurrent decompensation despite GDMT), persistent hypotension and low cardiac index (1.6 L/min/m²) after IV diuresis, elevated filling pressures (PCWP 32 mmHg, RAP 18 mmHg), severe functional MR, and advanced HFrEF with LVEF 20%. These indicate stage D heart failure requiring definitive mechanical support. The question asks for the best definitive next step, making durable LVAD implantation (D) the unique best choice as bridge to transplant or destination therapy per guidelines. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, as INTERMACS 4 explicitly guides advanced therapy candidacy, ruling out less definitive options. Main medical accuracy issue(s): None; aligns with ACC/AHA/ESC guidelines for LVAD in INTERMACS 4 patients with low-output symptoms, where isolated transplant (B) risks waitlist mortality without bridging, TEER (C) is adjunctive for stable patients, palliative inotropes (A) are for non-candidates, and percutaneous MCS (E) is temporary. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include INTERMACS profile 4 (recurrent decompensation despite GDMT), persistent hypotension and low cardiac index (1.6 L/min/m²) after IV diuresis, elevated filling pressures (PCWP 32 mmHg, RAP 18 mmHg), severe functional MR, and advanced HFrEF with LVEF 20%. These indicate stage D heart failure requiring definitive mechanical support. The question asks for the best definitive next step, making durable LVAD implantation (D) the unique best choice as bridge to transplant or destination therapy per guidelines. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, as INTERMACS 4 explicitly guides advanced therapy candidacy, ruling out less definitive options. Main medical accuracy issue(s): None; aligns with ACC/AHA/ESC guidelines for LVAD in INTERMACS 4 patients with low-output symptoms, where isolated transplant (B) risks waitlist mortality without bridging, TEER (C) is adjunctive for stable patients, palliative inotropes (A) are for non-candidates, and percutaneous MCS (E) is temporary. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-003", "question": "A previously healthy 4-year-old boy presents with 10 days of fever to 39.5°C, conjunctival injection without exudate, cracked lips, polymorphous trunk rash, edema and erythema of hands and feet, and cervical lymphadenopathy. Symptoms partially improved after ibuprofen but recur when stopped. Day-10 echocardiogram: diffuse coronary artery ectasia with z-scores 2.3-2.7, mild LV dysfunction (EF 50%), and small pericardial effusion. Labs: WBC 14,000/µL, platelets 520,000/µL, CRP 10 mg/dL, ESR 80 mm/hr, ALT mildly elevated, sterile pyuria. COVID serology and respiratory viral panel are negative. He has not yet received IVIG. What is the most appropriate initial treatment strategy now?", "options": ["Single dose IVIG 2 g/kg plus high-dose aspirin only", "IVIG 2 g/kg, high-dose aspirin, and a single dose of IV methylprednisolone 30 mg/kg", "IVIG 2 g/kg, low-dose aspirin, and infliximab 5 mg/kg", "IVIG 2 g/kg, high-dose aspirin, and anakinra 2 mg/kg/day", "High-dose aspirin alone because presentation is after day 10 of illness"], "answer": "B", "answer_index": 1, "explanation": "He has classic Kawasaki disease with coronary changes and delayed presentation, which confers high risk of IVIG resistance and coronary progression. Current risk-adapted approaches favor adjunctive corticosteroids with IVIG in high-risk patients (coronary involvement and very elevated inflammatory markers), even after day 10. Aspirin monotherapy is inadequate; biologics are reserved for IVIG-resistant disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the most appropriate initial treatment for a 4-year-old with classic Kawasaki disease (KD) presenting on day 10 with ongoing fever, coronary artery ectasia (z-scores 2.3-2.7), mild LV dysfunction, and elevated inflammatory markers (CRP 10 mg/dL, ESR 80 mm/hr). Key stem clues driving unique best answer: prolonged fever, full KD criteria met, coronary involvement indicating high risk for IVIG resistance, no prior IVIG, persistent symptoms despite ibuprofen. Most likely diagnosis: KD with cardiac complications. Keyed answer B fits as it combines standard IVIG 2 g/kg and high-dose aspirin with adjunctive methylprednisolone 30 mg/kg for high-risk features, per current risk-adapted approaches to reduce coronary progression. Alternatives: A omits steroids despite high-risk indicators; C uses low-dose aspirin (inappropriate initially) and infliximab (reserved for refractory cases); D employs anakinra (also for IVIG resistance, not initial); E inadequately forgoes IVIG, as guidelines support IVIG beyond day 10 with ongoing inflammation. No main logical issues; stem allows discrimination with comparable options. No medical accuracy issues; aligns with AHA guidelines and studies (e.g., RAISE trial) favoring upfront corticosteroids in high-risk KD, even delayed. Minimal fix: None needed, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem asks for the most appropriate initial treatment for a 4-year-old with classic Kawasaki disease (KD) presenting on day 10 with ongoing fever, coronary artery ectasia (z-scores 2.3-2.7), mild LV dysfunction, and elevated inflammatory markers (CRP 10 mg/dL, ESR 80 mm/hr). Key stem clues driving unique best answer: prolonged fever, full KD criteria met, coronary involvement indicating high risk for IVIG resistance, no prior IVIG, persistent symptoms despite ibuprofen. Most likely diagnosis: KD with cardiac complications. Keyed answer B fits as it combines standard IVIG 2 g/kg and high-dose aspirin with adjunctive methylprednisolone 30 mg/kg for high-risk features, per current risk-adapted approaches to reduce coronary progression. Alternatives: A omits steroids despite high-risk indicators; C uses low-dose aspirin (inappropriate initially) and infliximab (reserved for refractory cases); D employs anakinra (also for IVIG resistance, not initial); E inadequately forgoes IVIG, as guidelines support IVIG beyond day 10 with ongoing inflammation. No main logical issues; stem allows discrimination with comparable options. No medical accuracy issues; aligns with AHA guidelines and studies (e.g., RAISE trial) favoring upfront corticosteroids in high-risk KD, even delayed. Minimal fix: None needed, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-004", "question": "A 32-year-old woman with mixed connective tissue disease (U1-RNP positive) on mycophenolate mofetil and low-dose prednisone presents with 3 months of progressive exertional dyspnea and near-syncope. Exam: loud P2, right ventricular heave, no crackles, no edema. HR 94, BP 108/68 mmHg, O2 sat 95% on room air. CT chest: no interstitial lung disease, no PE. TTE: normal LV, moderately dilated RV with reduced function, estimated PASP 75 mmHg, no shunt. Right heart cath: mPAP 46 mmHg, PAOP 9 mmHg, CI 2.0 L/min/m², PVR 9 Wood units. Autoantibodies: strong anti-U1-RNP, negative anti-Scl-70. She desires pregnancy within 1-2 years. What is the most appropriate initial advanced therapy strategy for her pulmonary hypertension?", "options": ["Start amlodipine after acute vasoreactivity testing, then titrate based on BP", "Initiate dual oral therapy with ambrisentan and tadalafil", "Initiate triple therapy including IV epoprostenol plus an endothelin receptor antagonist and a PDE-5 inhibitor", "Start inhaled treprostinil monotherapy and observe functional response", "Use riociguat monotherapy given connective tissue disease-associated PAH"], "answer": "C", "answer_index": 2, "explanation": "She has high-risk WHO group 1 CTD-associated PAH (RV dysfunction, mPAP 46, CI 2.0, PVR 9) and plans pregnancy (a major risk), warranting aggressive up-front therapy. Modern guidelines recommend initial triple therapy with parenteral prostacyclin in high-risk PAH patients. CCBs are only for acute vasoreactivity responders; dual or single oral agents are insufficient for this profile.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include high-risk features (RV dysfunction, mPAP 46 mmHg, CI 2.0 L/min/m², PVR 9 Wood units), CTD-associated PAH (U1-RNP positive, negative anti-Scl-70), and desire for pregnancy within 1-2 years, which heightens urgency for aggressive control given PAH's contraindication in pregnancy. These support initial triple therapy with IV epoprostenol plus ERA and PDE-5i as the most appropriate strategy per modern guidelines (e.g., ESC/ERS) for high-risk group 1 PAH, especially in CTD with poor prognosis and reproductive plans. Main logical issue(s): none; the stem provides sufficient discriminating details (RHC values, echo findings, autoantibody profile) to identify C as uniquely best without contradictions or underspecification. Alternatives are inferior: A requires vasoreactivity not mentioned; B is dual oral for lower risk; D is monotherapy; E is riociguat alone, not preferred in CTD-PAH. Main medical accuracy issue(s): none; aligns with current standards emphasizing upfront parenteral prostacyclin in high-risk PAH and pregnancy risks. Minimal fix: No edit needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include high-risk features (RV dysfunction, mPAP 46 mmHg, CI 2.0 L/min/m², PVR 9 Wood units), CTD-associated PAH (U1-RNP positive, negative anti-Scl-70), and desire for pregnancy within 1-2 years, which heightens urgency for aggressive control given PAH's contraindication in pregnancy. These support initial triple therapy with IV epoprostenol plus ERA and PDE-5i as the most appropriate strategy per modern guidelines (e.g., ESC/ERS) for high-risk group 1 PAH, especially in CTD with poor prognosis and reproductive plans. Main logical issue(s): none; the stem provides sufficient discriminating details (RHC values, echo findings, autoantibody profile) to identify C as uniquely best without contradictions or underspecification. Alternatives are inferior: A requires vasoreactivity not mentioned; B is dual oral for lower risk; D is monotherapy; E is riociguat alone, not preferred in CTD-PAH. Main medical accuracy issue(s): none; aligns with current standards emphasizing upfront parenteral prostacyclin in high-risk PAH and pregnancy risks. Minimal fix: No edit needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-005", "question": "A 24-year-old primigravida at 11 weeks presents with severe nausea, non-bloody emesis 10-15 times daily, 4-kg weight loss, orthostatic tachycardia, and inability to keep down oral medications despite pyridoxine/doxylamine and rectal promethazine. She has ketonuria, Na 131 mEq/L, K 2.9 mEq/L, bicarbonate 19 mEq/L, ALT 78 U/L, AST 65 U/L, normal lipase and thyroid function. Ultrasound: single viable intrauterine pregnancy. She requests to avoid hospitalization if possible and is anxious about teratogenic risk. What is the most appropriate next-step pharmacologic management in addition to IV fluids and electrolyte repletion?", "options": ["Start oral ondansetron and allow discharge with close outpatient follow-up", "Begin continuous subcutaneous metoclopramide infusion as an outpatient", "Administer IV ondansetron and admit for parenteral nutrition via PICC line", "Start transdermal scopolamine and oral mirtazapine", "Administer IV chlorpromazine now and transition to scheduled IV ondansetron or metoclopramide in the hospital"], "answer": "E", "answer_index": 4, "explanation": "She has hyperemesis gravidarum with significant volume depletion and electrolyte derangements, requiring inpatient care and parenteral antiemetics. Phenothiazines (e.g., IV chlorpromazine) followed by scheduled IV ondansetron or metoclopramide are evidence-based for refractory hyperemesis. Outpatient oral or SC regimens are inappropriate given inability to tolerate PO; TPN is reserved for failure of intensive antiemetic therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe refractory hyperemesis gravidarum with daily vomiting 10-15 times, 4-kg weight loss, orthostatic tachycardia, ketonuria, hyponatremia (Na 131), hypokalemia (K 2.9), metabolic acidosis (bicarb 19), mild transaminitis (ALT 78, AST 65), and failure of pyridoxine/doxylamine plus rectal promethazine, despite patient preference to avoid hospitalization. These indicate significant dehydration and electrolyte derangements necessitating inpatient parenteral antiemetics over outpatient options. No main logical issues: stem is consistent, supports E as unique best by requiring hospital-based IV therapy for refractory symptoms, with options discriminable based on route, setting, and aggressiveness. No main medical accuracy issues: aligns with ACOG guidelines for hyperemesis management, escalating to IV phenothiazines (e.g., chlorpromazine) then scheduled IV ondansetron or metoclopramide for severe cases; TPN (as in C) is reserved for failures; outpatient regimens (A, B, D) inappropriate given PO intolerance and severity. Minimal fix: None needed, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe refractory hyperemesis gravidarum with daily vomiting 10-15 times, 4-kg weight loss, orthostatic tachycardia, ketonuria, hyponatremia (Na 131), hypokalemia (K 2.9), metabolic acidosis (bicarb 19), mild transaminitis (ALT 78, AST 65), and failure of pyridoxine/doxylamine plus rectal promethazine, despite patient preference to avoid hospitalization. These indicate significant dehydration and electrolyte derangements necessitating inpatient parenteral antiemetics over outpatient options. No main logical issues: stem is consistent, supports E as unique best by requiring hospital-based IV therapy for refractory symptoms, with options discriminable based on route, setting, and aggressiveness. No main medical accuracy issues: aligns with ACOG guidelines for hyperemesis management, escalating to IV phenothiazines (e.g., chlorpromazine) then scheduled IV ondansetron or metoclopramide for severe cases; TPN (as in C) is reserved for failures; outpatient regimens (A, B, D) inappropriate given PO intolerance and severity. Minimal fix: None needed, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-006", "question": "A 17-year-old previously healthy boy is admitted to the ICU with septic shock due to meningococcemia, requiring norepinephrine and mechanical ventilation. On day 4, BP stabilizes and pressors are stopped. Over the next 24 hours, he develops rapidly worsening hypoxemia with PaO2/FiO2 ratio 90, diffuse bilateral infiltrates, and new hemoptysis. Hb drops from 11 to 8 g/dL without obvious bleeding. Platelets are 220,000/µL, PT/INR normal, PTT normal, fibrinogen 400 mg/dL. Urinalysis: 3+ blood, 2+ protein, many dysmorphic RBCs. Creatinine rises from 0.8 to 2.1 mg/dL. ANA negative, ANCA panel negative, complements normal. Bronchoscopy shows diffuse alveolar hemorrhage; cultures pending. What is the most appropriate next step in management?", "options": ["High-dose IV methylprednisolone and IV cyclophosphamide for presumed ANCA-negative pulmonary-renal vasculitis", "Plasmapheresis plus pulse steroids for suspected anti-GBM disease despite negative serology", "Supportive care only, assuming septic coagulopathy-related lung injury", "Kidney biopsy as soon as feasible to guide immunosuppression decisions", "Start rituximab and prednisone for suspected immune-complex GN related to sepsis"], "answer": "D", "answer_index": 3, "explanation": "He has a pulmonary-renal syndrome with DAH and GN but negative ANCA/anti-GBM serologies and preserved platelets/coagulation, making pure septic DIC unlikely. In this critically ill patient, tissue diagnosis is essential before committing to aggressive immunosuppression, especially with negative serologies. Early kidney biopsy best clarifies the etiology; empiric cytotoxic therapy or plasmapheresis without diagnosis carries high risk and may be inappropriate if the lesion is infection-related.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include resolved septic shock from meningococcemia, new diffuse alveolar hemorrhage (DAH) with hemoptysis and hypoxemia, hemoglobin drop without overt bleeding, hematuria with dysmorphic RBCs, acute kidney injury (AKI), negative ANA/ANCA/complements, and normal platelets/coagulation excluding DIC. These suggest pulmonary-renal syndrome possibly due to vasculitis, anti-GBM, or post-infectious glomerulonephritis (GN), but negative serologies and sepsis context necessitate diagnostic confirmation before immunosuppression. Main logical issue(s): none; the stem provides sufficient discriminating findings to identify kidney biopsy (D) as the single best next step, avoiding empiric therapies in A, B, E that assume unconfirmed diagnoses, and rejecting C's supportive care which ignores progressive renal involvement. Main medical accuracy issue(s): none; aligns with guidelines for pulmonary-renal syndromes where biopsy guides management in seronegative cases, especially post-infection, per nephrology standards (e.g., KDIGO). Minimal fix: none needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include resolved septic shock from meningococcemia, new diffuse alveolar hemorrhage (DAH) with hemoptysis and hypoxemia, hemoglobin drop without overt bleeding, hematuria with dysmorphic RBCs, acute kidney injury (AKI), negative ANA/ANCA/complements, and normal platelets/coagulation excluding DIC. These suggest pulmonary-renal syndrome possibly due to vasculitis, anti-GBM, or post-infectious glomerulonephritis (GN), but negative serologies and sepsis context necessitate diagnostic confirmation before immunosuppression. Main logical issue(s): none; the stem provides sufficient discriminating findings to identify kidney biopsy (D) as the single best next step, avoiding empiric therapies in A, B, E that assume unconfirmed diagnoses, and rejecting C's supportive care which ignores progressive renal involvement. Main medical accuracy issue(s): none; aligns with guidelines for pulmonary-renal syndromes where biopsy guides management in seronegative cases, especially post-infection, per nephrology standards (e.g., KDIGO). Minimal fix: none needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-007", "question": "A 6-week-old full-term girl presents with poor feeding, tachypnea, and sweating with feeds. Weight is at the 3rd percentile (previously 40th). Vitals: HR 180, RR 60, BP 70/40 mmHg in all extremities, O2 sat 96% RA. Exam: hepatomegaly, gallop rhythm, 2/6 holosystolic murmur at apex radiating to axilla, no differential pulses. CXR: cardiomegaly, pulmonary overcirculation. Echo: dilated LV with EF 20%, moderate MR, normal coronaries, no coarctation or structural shunt, normal RV function. ECG: sinus tachycardia. Blood and viral studies pending. After starting IV milrinone and diuretics, she stabilizes. What is the MOST appropriate next step in definitive management planning?", "options": ["Discontinue inotropes as soon as EF improves above 35% and transition to oral heart failure therapy only", "Urgently list for heart transplant as status 1A given high mortality of infantile dilated cardiomyopathy", "Begin high-dose IVIG for presumed viral myocarditis and defer consideration of mechanical support", "Evaluate for durable LVAD candidacy as bridge to transplant or recovery", "Schedule elective mitral valve repair to reduce regurgitation and improve LV function"], "answer": "D", "answer_index": 3, "explanation": "She has severe idiopathic/viral dilated cardiomyopathy with EF 20% and inotrope dependence, placing her at high risk of deterioration. Early evaluation for durable LVAD as bridge to transplant or recovery is recommended in infants with advanced heart failure who respond incompletely to medical therapy. Immediate transplant listing without MCS may be risky given wait times; valve surgery will not address primary LV dysfunction; IVIG alone is insufficient as definitive strategy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 6-week-old with acute heart failure symptoms, weight faltering, tachycardia, tachypnea, low BP, hepatomegaly, gallop, holosystolic murmur, cardiomegaly with pulmonary overcirculation, dilated LV with EF 20%, moderate MR, normal coronaries/RV, stabilization on milrinone/diuretics, pending viral studies—pointing to severe infantile dilated cardiomyopathy (likely idiopathic/viral) with inotrope dependence.\\nMain logical issue(s), if any: None; stem provides sufficient discriminating findings (e.g., low EF, LV dilation, no structural defects) to identify D as uniquely best next step for definitive management, with alternatives inferior based on risk and pathophysiology.\\nMain medical accuracy issue(s), if any: None; aligns with pediatric cardiology guidelines (e.g., ISHLT) recommending early MCS evaluation in infants with advanced HF unresponsive to medical optimization, as bridge to transplant/recovery; IVIG appropriate if viral confirmed but not definitive alone; valve repair addresses secondary MR ineffectively.\\nMinimal fix: None needed; item is unambiguous and accurate.\\n\\nBest-answer defensibility: a) Question asks for most appropriate next step in definitive management of infantile DCM with severe LV dysfunction. b) Key clues: poor feeding/sweating, low EF 20%, moderate MR, stabilization on inotropes/diuretics, no anomalies. c) Most likely: advanced heart failure needing MCS bridge. d) D fits as early LVAD eval addresses high deterioration risk per guidelines; assumes standard pediatric HF protocols. e) A worse: premature de-escalation risks decompensation; B: listing without bridge risky due to wait times; C: IVIG insufficient alone, defers MCS; E: surgery won't fix primary LV issue.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 6-week-old with acute heart failure symptoms, weight faltering, tachycardia, tachypnea, low BP, hepatomegaly, gallop, holosystolic murmur, cardiomegaly with pulmonary overcirculation, dilated LV with EF 20%, moderate MR, normal coronaries/RV, stabilization on milrinone/diuretics, pending viral studies—pointing to severe infantile dilated cardiomyopathy (likely idiopathic/viral) with inotrope dependence.\nMain logical issue(s), if any: None; stem provides sufficient discriminating findings (e.g., low EF, LV dilation, no structural defects) to identify D as uniquely best next step for definitive management, with alternatives inferior based on risk and pathophysiology.\nMain medical accuracy issue(s), if any: None; aligns with pediatric cardiology guidelines (e.g., ISHLT) recommending early MCS evaluation in infants with advanced HF unresponsive to medical optimization, as bridge to transplant/recovery; IVIG appropriate if viral confirmed but not definitive alone; valve repair addresses secondary MR ineffectively.\nMinimal fix: None needed; item is unambiguous and accurate.\n\nBest-answer defensibility: a) Question asks for most appropriate next step in definitive management of infantile DCM with severe LV dysfunction. b) Key clues: poor feeding/sweating, low EF 20%, moderate MR, stabilization on inotropes/diuretics, no anomalies. c) Most likely: advanced heart failure needing MCS bridge. d) D fits as early LVAD eval addresses high deterioration risk per guidelines; assumes standard pediatric HF protocols. e) A worse: premature de-escalation risks decompensation; B: listing without bridge risky due to wait times; C: IVIG insufficient alone, defers MCS; E: surgery won't fix primary LV issue.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-008", "question": "A 29-year-old woman at 36+1 weeks with known SLE (class IV lupus nephritis in remission on azathioprine and hydroxychloroquine) presents with 3 days of severe frontal headache, visual blurring, and increasing lower extremity edema. BP 164/102 mmHg (baseline 110/70), HR 92. Labs: platelets 185,000/µL, AST 40 U/L, ALT 35 U/L, creatinine 1.3 mg/dL (baseline 1.1), urine protein/creatinine ratio 2.2 (baseline 1.8), C3 and C4 low, anti-dsDNA titer increased from 1:80 to 1:320, urinalysis with active sediment (RBC casts). Fetus is cephalic, reassuring NST. What is the most appropriate management strategy?", "options": ["Diagnose superimposed preeclampsia with severe features and proceed to immediate delivery", "Increase azathioprine dose and schedule induction at 39 weeks if no further worsening", "Administer IV methylprednisolone for suspected lupus nephritis flare and continue pregnancy with close monitoring", "Start magnesium sulfate and attempt blood pressure control; delay delivery until 37 weeks", "Add IV cyclophosphamide for nephritis flare and plan delivery after disease control"], "answer": "C", "answer_index": 2, "explanation": "She has overlapping features but labs favor SLE flare: rising dsDNA, low complement, active urinary sediment with only mild new proteinuria and preserved platelets/LFTs. At 36 weeks, severe preeclampsia would typically show worsening proteinuria and other end-organ features. Pulse steroids for lupus nephritis flare while continuing pregnancy with close monitoring is appropriate; immediate delivery is not mandatory unless maternal or fetal status deteriorates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: At 36+1 weeks, SLE patient with class IV lupus nephritis in remission presents with headache, visual blurring, edema, new hypertension (164/102 mmHg), mild creatinine rise (1.3 mg/dL), mild proteinuria increase (UPCR 2.2), normal platelets (185,000/µL) and LFTs (AST 40, ALT 35), low C3/C4, rising anti-dsDNA (1:80 to 1:320), and urinalysis with RBC casts; fetus reassuring. These favor lupus nephritis flare over superimposed preeclampsia due to active sediment, serologic activity, and absence of severe end-organ dysfunction like thrombocytopenia or elevated LFTs. Main logical issue(s): None; stem provides sufficient discriminating details (serologies, mild changes, preserved platelets/LFTs) to identify C as uniquely best—IV methylprednisolone for flare with monitoring—without contradictions or underspecification. Alternatives are inferior: A assumes preeclampsia despite flare indicators; B inadequately addresses acute flare; D treats as preeclampsia without flare management; E uses teratogenic cyclophosphamide in pregnancy. Main medical accuracy issue(s): None; aligns with ACOG/RCOG guidelines distinguishing lupus flare (low complements, rising dsDNA, casts) from preeclampsia, favoring steroids for flare at late preterm with monitoring unless deterioration. Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: At 36+1 weeks, SLE patient with class IV lupus nephritis in remission presents with headache, visual blurring, edema, new hypertension (164/102 mmHg), mild creatinine rise (1.3 mg/dL), mild proteinuria increase (UPCR 2.2), normal platelets (185,000/µL) and LFTs (AST 40, ALT 35), low C3/C4, rising anti-dsDNA (1:80 to 1:320), and urinalysis with RBC casts; fetus reassuring. These favor lupus nephritis flare over superimposed preeclampsia due to active sediment, serologic activity, and absence of severe end-organ dysfunction like thrombocytopenia or elevated LFTs. Main logical issue(s): None; stem provides sufficient discriminating details (serologies, mild changes, preserved platelets/LFTs) to identify C as uniquely best—IV methylprednisolone for flare with monitoring—without contradictions or underspecification. Alternatives are inferior: A assumes preeclampsia despite flare indicators; B inadequately addresses acute flare; D treats as preeclampsia without flare management; E uses teratogenic cyclophosphamide in pregnancy. Main medical accuracy issue(s): None; aligns with ACOG/RCOG guidelines distinguishing lupus flare (low complements, rising dsDNA, casts) from preeclampsia, favoring steroids for flare at late preterm with monitoring unless deterioration. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-009", "question": "An intubated 65-year-old woman with severe influenza A pneumonia develops refractory hypoxemia despite lung-protective ventilation (TV 6 mL/kg, PEEP 14 cm H2O, FiO2 0.9) and paralysis. PaO2/FiO2 ratio is 70. She is placed on prone positioning for 16 hours/day with transient improvement but remains PaO2/FiO2 <80. Hemodynamics: MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L. No significant comorbidities; BMI 30 kg/m². Family consents to aggressive support. The center has on-site ECMO with experienced team but limited capacity. Which of the following is the most appropriate next step?", "options": ["Increase PEEP to 20 cm H2O and accept permissive hypercapnia before considering ECMO", "Initiate venovenous ECMO now due to refractory severe ARDS despite optimal conventional therapy", "Switch to high-frequency oscillatory ventilation for rescue oxygenation", "Trial inhaled nitric oxide and further proning cycles before deciding on ECMO", "Initiate venoarterial ECMO because of concurrent vasopressor use"], "answer": "B", "answer_index": 1, "explanation": "She has severe ARDS with PaO2/FiO2 <80 despite optimal lung-protective ventilation, high PEEP, paralysis, and proning-meeting criteria for VV-ECMO in an experienced center. Further escalation of ventilator settings or oscillatory ventilation adds risk with limited additional benefit. Low-dose vasopressor does not mandate VA-ECMO; VV-ECMO is appropriate when cardiac function is adequate and shock is not predominant.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Refractory hypoxemia in severe ARDS (PaO2/FiO2 <80) despite optimal conventional therapies including lung-protective ventilation (TV 6 mL/kg, PEEP 14), paralysis, and prone positioning; stable hemodynamics (MAP 72 on low-dose norepinephrine, normal lactate); on-site ECMO availability with experienced team and family consent for aggressive support. These findings meet established criteria for VV-ECMO initiation in refractory severe ARDS per guidelines like EOLIA trial and ATS/ERS recommendations. Main logical issue(s): None; stem provides sufficient details to discriminate B as uniquely best without contradictions or underspecification. Alternatives are inferior: A risks barotrauma from excessive PEEP; C uses HFOV, which is outdated and not recommended; D trials iNO, lacking strong evidence for mortality benefit in ARDS; E opts for VA-ECMO unnecessarily, as vasopressor use is low-dose and not indicative of predominant shock or cardiac failure. Main medical accuracy issue(s): None; aligns with current mainstream standards for ARDS management, emphasizing ECMO for refractory cases without promoting ineffective rescues. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Refractory hypoxemia in severe ARDS (PaO2/FiO2 <80) despite optimal conventional therapies including lung-protective ventilation (TV 6 mL/kg, PEEP 14), paralysis, and prone positioning; stable hemodynamics (MAP 72 on low-dose norepinephrine, normal lactate); on-site ECMO availability with experienced team and family consent for aggressive support. These findings meet established criteria for VV-ECMO initiation in refractory severe ARDS per guidelines like EOLIA trial and ATS/ERS recommendations. Main logical issue(s): None; stem provides sufficient details to discriminate B as uniquely best without contradictions or underspecification. Alternatives are inferior: A risks barotrauma from excessive PEEP; C uses HFOV, which is outdated and not recommended; D trials iNO, lacking strong evidence for mortality benefit in ARDS; E opts for VA-ECMO unnecessarily, as vasopressor use is low-dose and not indicative of predominant shock or cardiac failure. Main medical accuracy issue(s): None; aligns with current mainstream standards for ARDS management, emphasizing ECMO for refractory cases without promoting ineffective rescues. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-010", "question": "A 10-year-old boy with a history of intermittent asthma presents with 3 weeks of fever, weight loss, night sweats, and progressive joint pains. Exam: non-blanching palpable purpura on lower extremities, mononeuritis multiplex with foot drop, and hypertension (130/86 mmHg). No asthma exacerbation. Labs: ESR 90 mm/hr, CRP 12 mg/dL, creatinine 1.1 mg/dL, urinalysis with 1+ protein and few RBCs, hepatitis B surface antigen positive, high HBV DNA titer, negative ANCA. CT angiography: multiple microaneurysms in mesenteric and renal arteries. What is the most appropriate initial treatment strategy?", "options": ["High-dose corticosteroids plus cyclophosphamide without antiviral therapy", "Start entecavir and delay immunosuppression until HBV viral load is suppressed", "High-dose corticosteroids plus plasma exchange and antiviral therapy", "Rituximab with low-dose steroids and entecavir prophylaxis", "Plasma exchange and entecavir only, avoiding immunosuppression"], "answer": "C", "answer_index": 2, "explanation": "He has HBV-associated polyarteritis nodosa with medium-vessel aneurysms and high viral load. Management requires control of both vasculitis and viral replication: short-course high-dose steroids with plasma exchange and concurrent antiviral therapy is recommended. Prolonged cyclophosphamide without antivirals worsens HBV; antivirals alone are insufficient in active PAN; rituximab is less established in HBV-PAN.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is identifying the most appropriate initial treatment for a child with HBV-associated polyarteritis nodosa (PAN) presenting with systemic symptoms, vasculitis features, and high viral load. Key stem clues: 3 weeks fever, weight loss, night sweats, joint pains; palpable purpura, mononeuritis multiplex, hypertension; elevated ESR/CRP, mild renal involvement, positive HBsAg with high HBV DNA, negative ANCA, and CT angiography showing mesenteric/renal microaneurysms—classic for HBV-PAN, implying need to address both vasculitis and viral replication urgently. Most likely diagnosis: HBV-associated PAN. Keyed answer C fits: high-dose corticosteroids plus plasma exchange and antiviral therapy balances rapid vasculitis control with HBV suppression, per guidelines avoiding prolonged immunosuppression. Alternatives: A incorrect due to no antiviral, risking HBV flare; B delays needed immunosuppression for active disease; D uses rituximab, not first-line for PAN and less established in HBV context; E avoids immunosuppression entirely, insufficient for severe symptoms. No main logical issues; stem supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current standards (e.g., antiviral like entecavir with short steroids/plasmapheresis for severe HBV-PAN). Minimal fix: None needed.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The clinical problem is identifying the most appropriate initial treatment for a child with HBV-associated polyarteritis nodosa (PAN) presenting with systemic symptoms, vasculitis features, and high viral load. Key stem clues: 3 weeks fever, weight loss, night sweats, joint pains; palpable purpura, mononeuritis multiplex, hypertension; elevated ESR/CRP, mild renal involvement, positive HBsAg with high HBV DNA, negative ANCA, and CT angiography showing mesenteric/renal microaneurysms—classic for HBV-PAN, implying need to address both vasculitis and viral replication urgently. Most likely diagnosis: HBV-associated PAN. Keyed answer C fits: high-dose corticosteroids plus plasma exchange and antiviral therapy balances rapid vasculitis control with HBV suppression, per guidelines avoiding prolonged immunosuppression. Alternatives: A incorrect due to no antiviral, risking HBV flare; B delays needed immunosuppression for active disease; D uses rituximab, not first-line for PAN and less established in HBV context; E avoids immunosuppression entirely, insufficient for severe symptoms. No main logical issues; stem supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current standards (e.g., antiviral like entecavir with short steroids/plasmapheresis for severe HBV-PAN). Minimal fix: None needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]